ITGAM and cancer: To evaluate the clinical relevance of the crosstalk between Tu-Gr1+CD11b+ and tumor cells, we tested to determine whether the Tu-Gr1+CD11b+–induced 4T1 signature (top 50 DEGs) could predict cancer progression in other murine models and patients.